Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 21, 2021 - Issue 9
Submit an article Journal homepage
5,351
Views
13
CrossRef citations to date
0
Altmetric
Review

Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone

Peter Jennera Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UKCorrespondence[email protected]
View further author information
,
José-Francisco Rochab Department of Research & Development, BIAL – Portela & Ca SA, PortugalView further author information
,
Joaquim J Ferreirac Laboratory of Clinical Pharmacology and Therapeutics, Faculdade De Medicina, Universidade De Lisboa, Lisboa, Portugal;d CNS – Campus Neurológico, Torres Vedras, PortugalORCID Iconhttps://orcid.org/0000-0003-3950-5113View further author information
ORCID Icon,
Olivier Rascole Clinical Investigation Center CIC1436, Departments of Clinical Pharmacology and Neurosciences, NS-Park/FCRIN Network and Toulouse NeuroToul Coen Center; Inserm, University Hospital of Toulouse, and University of Toulouse 3, Toulouse, FranceView further author information
&
Patrício Soares-da-Silvab Department of Research & Development, BIAL – Portela & Ca SA, Portugal;f Department of Pharmacology and Therapeutics, Faculty of Medicine, University Porto, Porto, PortugalView further author information
Pages 1019-1033 | Received 29 Jun 2021, Accepted 11 Aug 2021, Published online: 15 Sep 2021

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Michael Serbin, Connie Marras, Carol Mansfield, Colton Leach, Charles Yonan, Margaret Sheehan, Anne Donnelly & Olga Klepitskaya. (2023) Patients’ Preferences for Adjunctive Parkinson’s Disease Treatments: A Discrete-Choice Experiment. Patient Preference and Adherence 17, pages 2263-2277.
Read now
Andrew Lees, Eduardo Tolosa, Fabrizio Stocchi, Joaquim J. Ferreira, Olivier Rascol, Angelo Antonini & Werner Poewe. (2023) Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Review of Neurotherapeutics 23:1, pages 15-24.
Read now
András Salamon, Dénes Zádori, László Szpisjak, Péter Klivényi & László Vécsei. (2022) What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?. Expert Opinion on Pharmacotherapy 23:10, pages 1123-1128.
Read now

Articles from other publishers (10)

Martin Regensburger, Chi Wang Ip, Zacharias Kohl, Christoph Schrader, Peter P. Urban, Jan Kassubek & Wolfgang H. Jost. (2023) Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations. Journal of Neural Transmission 130:6, pages 847-861.
Crossref
Gurkaran Singh Baweja, Shankar Gupta, Bhupinder Kumar, Preeti Patel & Vivek Asati. (2023) Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach. Molecular Diversity.
Crossref
Joana Rebouta, M. Luísa Dória, Filipa Campos, Francisca Araújo & Ana I. Loureiro. (2023) DESI-MSI-based technique to unravel spatial distribution of COMT inhibitor Tolcapone. International Journal of Pharmaceutics 633, pages 122607.
Crossref
Najeeb Ashraf. (2022) Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose Adjustment. European Medical Journal, pages 20-27.
Crossref
Luwen Xie, Xiaoyi Qi, Xuan Wang, Bing He, Yu Wang, Wei Zhang, Zehui Yu, Mingming Deng, Sicheng Liang & Muhan Lü. (2022) Adverse event profiles of adjuvant treatment with opicapone in Parkinson’s disease: A systematic review and meta-analysis. Frontiers in Pharmacology 13.
Crossref
Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Joana Moreira, Bruno Guimarães, José‐Francisco Rocha & Patrício Soares‐da‐Silva. (2022) Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease. Movement Disorders 37:11, pages 2272-2283.
Crossref
Ana I. Loureiro, Francisco Rocha, Ana T. Santos, Nand Singh, Maria João Bonifácio, Rui Pinto, Laszlo E. Kiss & Patrício Soares‐da‐Silva. (2022) Absorption, metabolism and excretion of opicapone in human healthy volunteers. British Journal of Clinical Pharmacology 88:10, pages 4540-4551.
Crossref
Wolfgang H. Jost, Carsten Buhmann, Joseph Classen, Karla Eggert, Zacharias Kohl, Tiago Outeiro, Lars Tönges, Dirk Woitalla & Heinz Reichmann. (2022) Stellenwert der COMT-Hemmer in der Therapie motorischer FluktuationenRelevance of COMT inhibitors in the treatment of motor fluctuations. Der Nervenarzt 93:10, pages 1035-1045.
Crossref
Diego Santos García, Gustavo Fernández Pajarín, Juan Manuel Oropesa-Ruiz, Francisco Escamilla Sevilla, Raúl Rashid Abdul Rahim López & José Guillermo Muñoz Enríquez. (2022) Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study. Brain Sciences 12:3, pages 383.
Crossref
Margherita Fabbri, Joaquim J. Ferreira & Olivier Rascol. (2022) COMT Inhibitors in the Management of Parkinson’s Disease. CNS Drugs 36:3, pages 261-282.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.